3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
12
Small Cell Lung Carcinoma
11
Fallopian Tube Neoplasms
9
Neuroblastoma
6
Neoplasm Metastasis
3
Lung Neoplasms
3
Ganglioneuroblastoma
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Sarcoma, Ewing
2
Rhabdoid Tumor
2
Recurrence
2
Leukemia, Myeloid, Acute
2
Glioma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Thrombocythemia, Essential
1
SCLC
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Pediatric Brain Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoma, Follicular
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
Paclitaxel
6
Mitomycin
3
Carboplatin
3
Bevacizumab
3
sodium thiosulfate
2
Laparoscopy
2
Hyperthermic Intraperitoneal Chemotherapy
2
Cisplatin
2
relacorilant
1
pembrolizumab
1
oregovomab
1
olaparib
1
nilotinib
1
liposomal doxorubicin
1
Topotecan
1
Taxes
1
Standard of Care
1
Specimen Handling
1
Saline Solution
1
Practice Guidelines as Topic
1
Pancreatectomy
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Laparotomy
1
Glucose
1
Gemcitabine
1
Fluorouracil
1
Electrocardiography
1
Doxorubicin
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
Topotecan
×
90 days
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled